top of page
About Us
Journal
Technology
Pipeline
Engage
The Healing Project
Canurta Naturals USA
FutureBotanica 2024
Canurta Day '23
Contact
Canurta Journal
A collection of news, scientific papers and impact across industry, academia and events.
All Posts
Research
Events
Awards
News
Blog
extractX Ltd. Signs Letter of Intent with Canurta Therapeutics: Accelerating Strategic Growth and CSE Listing via Amalgamation
Jun 23
The Science Behind Developing Plant-Based Medications
May 3
Canurta’s Research at the ALS/MND Symposium
Jan 22
Cannabinoids as Potential Therapeutics for ALS: An Overview from Preclinical and Clinical Studies
Dec 9, 2024
Optimization of Cannflavin Production in Germinated Hemp Seeds: Insights into Metabolomic and Antioxidant Profiles
Dec 2, 2024
Medical Marijuana for ALS Symptom Management: Potential Benefits and Risks in Disease Progression
Nov 25, 2024
Cannabistilbene I as a Potential Therapeutic for Cardiac Hypertrophy: Modulating Key Enzymes and Metabolic Pathways
Oct 11, 2024
3-Minute Pitch at ACT Canada Consortium: Advancing ALS Treatment with CNR-401
Oct 10, 2024
FDA Drug Approvals in 2023: Insights into Trends and Molecule Types
Aug 21, 2024
The Gut-Brain Axis: Exploring the Impact of Gut Microbiota-Derived Phenolic Compounds on Neurocognition
Aug 14, 2024
Cannflavin-C Counters Heart Enlargement Triggered by Angiotensin II: Impact on Enzymes and Fatty Acid Metabolism
Aug 7, 2024
Canurta Therapeutics Secures First US Patent for Novel Bioactive Polyphenol Extraction Process
Jul 31, 2024
Exploring Cannabis Pharmacology: Beyond THC and CBD
Jul 24, 2024
AI: Transforming the Future of Nutraceuticals
Jul 17, 2024
The Protective Role of Cannflavins A and B Against Cell Death in Human Skin Cells
Jul 8, 2024
Investigation of cannflavins from Cannabis sativa as potential anti-SARS-CoV-2 agents
Jul 1, 2024
The Antiatherogenic Potential of Flavonoids in Cardiovascular Health
Jun 24, 2024
Cannflavin A Displays Both a Hormetic and Neuroprotective Profile Against Alzheimer's Disease Progression
Jun 17, 2024
Preclinical Research with a First-in-Class ALS Therapy Formulation
May 24, 2024
Reflecting on the ALS Drug Development Summit in Boston
May 24, 2024
bottom of page